Table 1.
Baseline characteristics.
| Participants | 100 |
| Age, y | 45.2 ± 12.8 |
| Female, sex | 64 (64) |
| Ethnicity, Caucasian | 96 (96) |
| Blood pressure (systolic), mmHg | 133.9 ± 16.4 |
| Blood pressure (diastolic), mmHg | 82.2 ± 10.6 |
| Heart rate, bpm | 73.0 ± 12.0 |
| Height, m | 1.7 ± 0.1 |
| Weight, kg | 78.4 ± 17.8 |
| BMI, kg/m2 | 27.1 ± 5.2 |
| Oxygen saturation, % | 97.7 ± 1.2 |
| Temperature, °C | 36.5 ± 0.4 |
| Duration since index SARS-CoV-2 diagnosis (days) | 189 (125, 246) |
| History of hypertension | 12 (12) |
| History of diabetes mellitus | 1 (1) |
| History of Hypercholesterolemia | 20 (20) |
| History of Heart failure | 0 (0) |
| History of chronic obstructive pulmonary disease/asthma | 7 (7) |
| History of stroke | 1 (1) |
| History of deep vein thrombosis/pedal oedema | 5 (5) |
| New onset deep vein thrombosis/pedal oedema | 3/5 (60) |
| History of renal disease | 1 (1) |
| History of liver disease | 1 (1) |
| History of smoking | 41 (41) |
| Current | 9/41 (22) |
| Ex-smoker | 32/41 (78) |
| Average alcohol intake (units/week) | 8.3 ± 7.9 |
| Family history of premature coronary artery disease | 17 (17) |
| Long-term medications | |
| Aspirin | 3 (3) |
| Anticoagulants | 3 (3) |
| Angiotensin II receptor blockers | 5 (5) |
| Angiotensin-converting enzyme inhibitor | 1 (1) |
| Calcium channel blocker | 3 (3) |
| Lipid-lowering therapy | 7 (7) |
| Colchicine | 2 (2) |
| Antiarrhythmics | 2 (2) |
| SARS-CoV-2 infection | |
| Hospitalized for index SARS-CoV-2 infection | 14 (14) |
| Ventilatory support | 3/14 (21) |
| Invasive | 1/3 (33) |
| Hospitalization length (days) | 3 (1, 6.75) |
| Non-cardiac symptoms since infection | |
| Fever, % (persistent, resolved, never) | 3, 50, 47 |
| Sore throat, % (persistent, resolved, never) | 2, 29, 69 |
| Cough, % (persistent, resolved, never) | 4, 49, 47 |
| Myalgia, % (persistent, resolved, never) | 11, 63, 26 |
| Loss of sense of smell, % (persistent, resolved, never) | 17, 32, 51 |
| Loss of sense of taste, % (persistent, resolved, never) | 15, 31, 54 |
| Fatigue/Malaise, % (persistent, resolved, never) | 43, 43, 14 |
| Headache, % (persistent, resolved, never) | 22, 44, 34 |
| Rash, % (persistent, resolved, never) | 1, 9, 90 |
| GI disturbance, % (persistent, resolved, never) | 6, 33, 61 |
| Symptom severity during infection | |
| Severe | 18 (18) |
| Moderate | 35 (35) |
| Mild | 43 (43) |
| None | 4 (4) |
| Vaccination status | |
| Vaccinated for SARS-CoV-2 at index visit (at least one dose) | 60 (60) |
| Only one dose | 18/60 (30) |
| Fully vaccinated | 44/60 (73.3) |
| Type of vaccine | |
| Pfizer | 34/60 (56.7) |
| AstraZeneca | 21/60 (35) |
| Moderna | 3/60 (5) |
| Janssen | 2/60 (3.3) |
Data expressed as number (%), mean ± SD or median (interquartile range).